Company Statement

Biocon's Facility in Vishakhapatnam completes US FDA Inspection with no observations

Bengaluru, Karnataka, India, Sep 18, 2017-

This is to inform you that the US FDA inspected our Active Pharmaceutical Ingredients (API) manufacturing facility in Vishakhapatnam, Andhra Pradesh from Sep 11 to 15, 2017 and completed the audit without any observations. No form 483 was issued. The successful audit of this facility reflects our strong commitment to cGMP compliance at our manufacturing facilities.

-Company Spokesperson

MEDIA RELATIONS	INVESTOR RELATIONS
Seema Ahuja	**Saurabh Paliwal**
✆ +91 99723 17792	✆ +91 95383 80801
✉ seema.ahuja@biocon.com	✉ saurabh.paliwal@biocon.com